NCT03719482

Assessment of the Biodistribution and Safety of [18F]MNI-1054

Assessment of the Biodistribution and Safety of [18F]MNI-1054 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Invicro · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-1054 as a LSD1 targeted radiopharmaceutical.

Detailed description

The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-1054 as a LSD1 targeted radiopharmaceutical. The specific objectives are: * To determine the radiation dosimetry of \[18F\]MNI-1054 * To assess the safety and tolerability of a single dose of \[18F\]MNI-1054

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	[18F]MNI-1054	Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-1054 injection and PET scan.

Timeline

• Start date: 2018-10-05
• Primary completion: 2019-05-02
• Completion: 2019-05-02
• First posted: 2018-10-25
• Last updated: 2019-05-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study